BioCentury
ARTICLE | Financial News

Blueprint raises $300M in follow-on, speeds regulatory timelines

March 29, 2019 9:46 PM UTC

Days after revealing new timelines for its lead program, Blueprint raised $300 million in a follow-on priced late Thursday.

Blueprint Medicines Corp. (NASDAQ:BPMC) sold 4.1 million shares at $74, a 7% discount to the company's closing price of $79.88 on Wednesday, when it proposed the offering after market hours. Underwriters are Goldman Sachs, Cowen, Guggenheim and Wedbush...